Kelly A. Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly A. Campbell has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anna L. Wilson
University of South Florida
1 shared publication - Kimberly Fryer
Department of Obstetrics and Gynecology, Morsani College of Medicine University of South Florida Tampa Florida USA
1 shared publication - Kristen Whalen
University of South Florida Morsani College of Medicine
1 shared publication Lauren Kuykendall
Department of Plastic Surgery, University of South Florida , Tampa, FL
1 shared publicationMadison Tyle
University of South Florida Health Morsani College of Medicine , Tampa, FL
1 shared publicationMarilyn Torres
University of South Florida
1 shared publication
Latest Publications
- Open Access
- 7 May 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7
A Video Guide to Reshaping the Breast Through Staged Mastopexy After Nipple-Sparing Mastectomy
Background: Nipple Sparing Mastectomy (NSM) has gained popularity due to its improved aesthetics and oncological outcomes. This study focuses on staged mastopexy as a technique for optimizing aesthetics in patients with a history of NSM and implant-based reconstruction. Objectives: Our goal was to evaluate staged mastopexy as a technique to address complications such as implant and nipple-areolar complex malposition, rippling, and ptotic skin envelope, with a focus on patient selection, surgical technique, and patient-reported outcomes. Methods: We performed a retrospective analysis on a series of five patients who underwent NSM and immediate implant-based reconstruction with staged mastopexy by a single surgeon between 2020 and 2023. Descriptive analyses and t-tests were used. Significance was defined as p ≤ 0.05. Results: The cohort consisted of five patients (10 breasts) with a median age of 43 ± 6.5 years and average body mass index was 22.9 ± 2.2 kg/m2. The mean interval from mastectomy to mastopexy was 431.5 ± 232.1 days. Notably, no cases of partial or total nipple necrosis were observed. BREAST-Q surveys revealed significantly higher satisfaction scores for breasts (74. ± 19.9, p=0.01) compared to normative values, with an 80% response rate. Conclusions: Staged mastopexy demonstrates a safe and reproducible technique for correcting nipple and implant malposition following nipple sparing mastectomy and implant-based reconstruction.
- 7 May 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7
Open AccessA Video Guide to Reshaping the Breast Through Staged Mastopexy After Nipple-Sparing Mastectomy
Background: Nipple Sparing Mastectomy (NSM) has gained popularity due to its improved aesthetics and oncological outcomes. This study focuses on staged mastopexy as a technique for optimizing aesthetics in patients with a history of NSM and implant-based reconstruction. Objectives: Our goal was to evaluate staged mastopexy as a technique to address complications such as implant and nipple-areolar complex malposition, rippling, and ptotic skin envelope, with a focus on patient selection, surgical technique, and patient-reported outcomes. Methods: We performed a retrospective analysis on a series of five patients who underwent NSM and immediate implant-based reconstruction with staged mastopexy by a single surgeon between 2020 and 2023. Descriptive analyses and t-tests were used. Significance was defined as p ≤ 0.05. Results: The cohort consisted of five patients (10 breasts) with a median age of 43 ± 6.5 years and average body mass index was 22.9 ± 2.2 kg/m2. The mean interval from mastectomy to mastopexy was 431.5 ± 232.1 days. Notably, no cases of partial or total nipple necrosis were observed. BREAST-Q surveys revealed significantly higher satisfaction scores for breasts (74. ± 19.9, p=0.01) compared to normative values, with an 80% response rate. Conclusions: Staged mastopexy demonstrates a safe and reproducible technique for correcting nipple and implant malposition following nipple sparing mastectomy and implant-based reconstruction.
- 22 October 2024
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 51 (1) , 4-13
Risk factors of overdose in maternal patients with opioid use disorder: a scoping review
Background: Opioid-related overdoses significantly contribute to mortality in pregnancy and the postpartum period. Few studies report risk factors predisposing pregnant and postpartum patients with opioid use disorder (OUD) to overdose.Objective: This scoping review aims to describe the risk factors predisposing pregnant and postpartum patients with OUD to overdose.Method: Included studies identified pregnant and/or postpartum patients with OUD and differentiated between those who experienced overdose and those who did not. Of the 1060 articles, 8 met the criteria, examining 90,860 pregnant and postpartum patients with OUD.Results: Consistent use of medications for OUD (MOUD) during pregnancy and the postpartum period was the most frequently identified factor reducing overdose risk. Critical times of heightened overdose risk include the first trimester and the 7-12-month postpartum period. Pregnancy complications, such as stillbirth, severe maternal morbidity, preterm birth, and cesarean delivery, also increase risk. Opioid overdose is associated with being houseless, incarcerated, young, unmarried, publicly insured, not graduating high school, co-occurring substance use disorders, and inadequate prenatal care. Legislative changes, such as not classifying OUD in pregnancy as "child abuse" and increasing Medicaid reimbursement for Screening, Brief Intervention, and Referral to Treatment programs, are crucial to reducing risk. The impact of race and the influence of co-occurring psychiatric disorders was inconsistently reported.Conclusion: This scoping review identifies significant risk factors for opioid overdose in pregnant and postpartum patients. Improving access through enhanced Medicaid reimbursement, non-punitive reporting policies, and non-stigmatized care are keys to reducing overdose.
- 22 October 2024
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 51 (1) , 4-13
Risk factors of overdose in maternal patients with opioid use disorder: a scoping review
Background: Opioid-related overdoses significantly contribute to mortality in pregnancy and the postpartum period. Few studies report risk factors predisposing pregnant and postpartum patients with opioid use disorder (OUD) to overdose.Objective: This scoping review aims to describe the risk factors predisposing pregnant and postpartum patients with OUD to overdose.Method: Included studies identified pregnant and/or postpartum patients with OUD and differentiated between those who experienced overdose and those who did not. Of the 1060 articles, 8 met the criteria, examining 90,860 pregnant and postpartum patients with OUD.Results: Consistent use of medications for OUD (MOUD) during pregnancy and the postpartum period was the most frequently identified factor reducing overdose risk. Critical times of heightened overdose risk include the first trimester and the 7-12-month postpartum period. Pregnancy complications, such as stillbirth, severe maternal morbidity, preterm birth, and cesarean delivery, also increase risk. Opioid overdose is associated with being houseless, incarcerated, young, unmarried, publicly insured, not graduating high school, co-occurring substance use disorders, and inadequate prenatal care. Legislative changes, such as not classifying OUD in pregnancy as "child abuse" and increasing Medicaid reimbursement for Screening, Brief Intervention, and Referral to Treatment programs, are crucial to reducing risk. The impact of race and the influence of co-occurring psychiatric disorders was inconsistently reported.Conclusion: This scoping review identifies significant risk factors for opioid overdose in pregnant and postpartum patients. Improving access through enhanced Medicaid reimbursement, non-punitive reporting policies, and non-stigmatized care are keys to reducing overdose.